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terchangeable 300 and 400 mg dose. RESULTS: Model
data captured 99% of all feasible 2:1 interchanges. Cost
savings predicted form administrative data varied be-
tween 82 and 150 percent of actual savings using the pre-
scription direction model. CONCLUSIONS: Administra-
tive pharmacy data is a poor predictor of cost savings for
2:1 interchange protocols for medications with highly
variable dosing regimens such as gabapentin. A model
utilizing prescription directions may be beneficial in for-
mulary decision-making where highly accurate estimates
are necessary.
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OBJECTIVE: The Disability in Strategies for Care (DISC)
study compared, in 835 patients, a stratified care strat-
egy, where initial therapy for migraine is based on clini-
cal need, and two stepped care strategies (across attacks
and within attacks), where first-line therapy with simple
analgesic is escalated, if response has been inadequate, to
zolmitriptan—a migraine-specific therapy. We report on
a stochastic cost-effectiveness analysis (CEA) of these
three strategies. METHODS: The analysis adopted a so-
cietal perspective, including health service and productiv-
ity costs (1998–1999 prices). Data were collected on drug
usage (main therapy, rescue and adverse event manage-
ment); other resource use associated with adverse events
was estimated by a clinician blinded to treatment strat-
egy. Productivity costs were based on diary card data for
time patients lost from work, and on reduced effective-
ness at work. CEA related differential cost to the trial’s
two primary outcome measures: headache response at
two hours and disability-adjusted time over 4 hours. RE-
SULTS: Total mean cost over six attacks was lowest in
the stratified group (£138.95; 95% CI 122.38, 158.93)
compared to £157.19 (95% CI 134.50, 184.93) in the
stepped across attacks group and £148.53 (95% CI
123.04, 179.41) in the stepped care within attacks group.
Both measures of effectiveness showed an improvement
in the stratified arm. In terms of mean costs and effects,
stratified care represents a dominant strategy. Cost-effec-
tiveness acceptability curves indicate that, depending on
the value that decision-makers place on a unit of out-
come, the probability that stratified care is the most cost-
effective strategy ranges from 58% to 100% for the 2-
hour response rate and from 62% to 98% for disability-
adjusted time. CONCLUSION: Given its lower mean
costs and higher mean effectiveness, stratified care, which
included zolmitriptan, is the dominant strategy. When
uncertainty is considered, stratified care has the highest
probability of being cost-effective.
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OBJECTIVE: Estimate the long–term health and economic
impact in Sweden of treating patients with mild to moderate
Alzheimer’s disease (AD) with galantamine. METHODS:
The estimates are derived from an economic model con-
sisting of two parts. The short–term component was based
on the galantamine clinical trials. The long-term compo-
nent predicted, on the basis of trial results and equations
derived from recently published data, when patients
would require full time care (FTC) or die. Resources used
before FTC and for FTC were estimated from the litera-
ture, using an overall health care payer perspective. RE-
SULTS: Approximately 5.6 patients must start treatment
to avoid one year of FTC. Overall net savings of galan-
tamine compared to no treatment ranged from SEK
27,500 (all subjects) to SEK 59,000 (moderate patients
only). Univariate and multivariate sensitivity analyses of
key parameters, such as the cost of galantamine, cost of
FTC not in a nursing home (NH), cost of FTC in NH and
proportion of FTC patients in NH, supported the robust-
ness of these findings. For instance, a multivariate sensi-
tivity analysis found that if the cost of FTC outside a NH
is 50% of NH costs, instead of the 71% reported in the
literature, and only 50% of patients requiring FTC reside
in NH instead of the reported 85%, the net savings are
SEK 10,400. CONCLUSION: Galantamine therapy de-
lays the need for FTC without leading to additional cost
in the treatment of mild to moderate AD in Sweden.
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OBJECTIVES: Epilepsy and its treatment can have pro-
found effects on the quality of life (QOL) of many pa-
tients, particularly those with seizures refractory to treat-
ment. Detecting changes in QOL in trials of anti-epileptic
drugs as add-on therapy over a short period is, however,
known to be difficult. METHODS: In this study, we ex-
amined the relationship between patients’ perception of
quality of life change, using QOL transition scales, and
